98.68
0.50%
0.49
前日終値:
$98.19
開ける:
$98.99
24時間の取引高:
419.86K
Relative Volume:
0.92
時価総額:
$4.65B
収益:
$291.49M
当期純損益:
$-308.55M
株価収益率:
-21.78
EPS:
-4.53
ネットキャッシュフロー:
$-168.02M
1週間 パフォーマンス:
+5.91%
1か月 パフォーマンス:
+6.80%
6か月 パフォーマンス:
+28.51%
1年 パフォーマンス:
+64.19%
Axsome Therapeutics Inc Stock (AXSM) Company Profile
名前
Axsome Therapeutics Inc
セクター
電話
(212) 332-3241
住所
ONE WORLD TRADE CENTER, 22ND FLOOR, NEW YORK
AXSM を他の銘柄と比較する
株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
---|---|---|---|---|---|---|
AXSM | 98.68 | 4.65B | 291.49M | -308.55M | -168.02M | -4.53 |
VRTX | 450.97 | 116.38B | 10.63B | -479.80M | -1.35B | 13.33 |
REGN | 738.00 | 82.09B | 13.85B | 4.65B | 3.32B | 35.06 |
ARGX | 605.92 | 36.14B | 1.86B | -40.29M | -1.28B | -4.16 |
ALNY | 244.89 | 31.59B | 2.09B | -332.26M | 16.06M | -4.14 |
BNTX | 113.13 | 27.25B | 3.30B | -501.07M | 1.03B | 11.54 |
Axsome Therapeutics Inc Stock (AXSM) Upgrades & Downgrades
日付 | アクション | アナリスト | 評価の変更 |
---|---|---|---|
2024-09-03 | 開始されました | Wells Fargo | Overweight |
2024-08-06 | アップグレード | BofA Securities | Neutral → Buy |
2024-07-22 | 開始されました | Needham | Buy |
2024-04-29 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
2024-03-19 | 開始されました | Robert W. Baird | Outperform |
2024-02-06 | 開始されました | UBS | Buy |
2024-01-25 | 開始されました | RBC Capital Mkts | Outperform |
2023-12-13 | 開始されました | Citigroup | Buy |
2023-08-08 | アップグレード | BofA Securities | Underperform → Neutral |
2023-01-05 | 開始されました | Piper Sandler | Neutral |
2022-11-01 | 開始されました | Loop Capital | Buy |
2022-09-07 | 再開されました | Mizuho | Buy |
2021-08-10 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
2021-06-10 | 開始されました | Berenberg | Buy |
2021-01-08 | 開始されました | Jefferies | Buy |
2020-12-16 | 開始されました | Mizuho | Buy |
2020-09-29 | 開始されました | BofA Securities | Underperform |
2020-09-10 | 開始されました | Morgan Stanley | Overweight |
2020-04-28 | 繰り返されました | H.C. Wainwright | Buy |
2020-04-14 | 開始されました | Cowen | Outperform |
2019-12-30 | 繰り返されました | H.C. Wainwright | Buy |
2019-12-17 | 繰り返されました | H.C. Wainwright | Buy |
2019-12-16 | 繰り返されました | Guggenheim | Buy |
2019-10-16 | 開始されました | Guggenheim | Buy |
2019-09-18 | 開始されました | William Blair | Outperform |
2019-05-28 | 開始されました | SunTrust | Buy |
2019-05-23 | 繰り返されました | H.C. Wainwright | Buy |
2019-04-08 | 開始されました | SVB Leerink | Outperform |
2019-03-15 | 繰り返されました | H.C. Wainwright | Buy |
2016-10-03 | 再開されました | Brean Capital | Buy |
2015-12-15 | 開始されました | Cantor Fitzgerald | Buy |
2015-12-14 | 開始されました | Ladenburg Thalmann | Buy |
すべてを表示
Axsome Therapeutics Inc (AXSM) 最新ニュース
Migraine Market Forecasted to Surge in Coming Years, 2023-2032 Analysis by DelveInsight | Amgen, Teva Pharma, Eli Lilly, Teva Pharma, Axsome Therapeutics, AEON Biopharma, Charleston Laboratories - Barchart
Migraine Market Forecasted to Surge in Coming Years, 2023-2032 - openPR
Excessive Daytime Sleepiness Market to Witness Growth During the Forecast Period | Takeda, Theranexus, XW Pharma, Avadel, Axsome Therapeutics, Benevolent AI Bio - The Globe and Mail
(AXSM) Long Term Investment Analysis - Stock Traders Daily
Axsome Therapeutics' SWOT analysis: strong pipeline, sales growth boost stock outlook - Investing.com
StockNews.com Upgrades Axsome Therapeutics (NASDAQ:AXSM) to "Hold" - MarketBeat
Axsome's Q3 Earnings Beat, Auvelity Drives Sales Growth, Stock Up - MSN
Royce & Associates LP Has $2.02 Million Stock Position in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
First Turn Management LLC Sells 81,952 Shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Is It Too Late to Buy Viking Therapeutics Stock? - The Motley Fool
FY2024 EPS Estimates for AXSM Increased by Leerink Partnrs - MarketBeat
Axsome Therapeutics (AXSM) Q3 2024 Earnings Call Transcript - AOL
Axsome Therapeutics Inc (AXSM) Quarterly 10-Q Report - Quartzy
Axsome Advances Sleep Disorder Pipeline as Sunosi Prescriptions Increase in Q3 - Sleep Review
Equities Analysts Offer Predictions for AXSM FY2027 Earnings - MarketBeat
William Blair Issues Pessimistic Outlook for AXSM Earnings - MarketBeat
Axsome stock price target increased, rating held on strong sales - Investing.com
Axsome stock price target increased, rating held on strong sales By Investing.com - Investing.com UK
Axsome Therapeutics stock hits 52-week high at $98.61 By Investing.com - Investing.com Nigeria
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Q3 2024 Earnings Call Transcript - Insider Monkey
Robert W. Baird Raises Axsome Therapeutics (NASDAQ:AXSM) Price Target to $116.00 - MarketBeat
Earnings call: Axsome Therapeutics reports record quarterly revenue By Investing.com - Investing.com Australia
Versor Investments LP Acquires New Holdings in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Axsome Therapeutics’ Strong Q3 Growth Amidst Strategic Expansions - TipRanks
Axsome: Q3 Earnings Snapshot - Houston Chronicle
Earnings call: Axsome Therapeutics reports record quarterly revenue - Investing.com
Axsome Therapeutics stock hits 52-week high at $98.61 - Investing.com India
Axsome shares rise as Guggenheim lifts target to $135 By Investing.com - Investing.com UK
Axsome Therapeutics Q3 Earnings: Stay For Near Term Catalysts, Then Sell (AXSM) - Seeking Alpha
Axsome Therapeutics (NASDAQ:AXSM) Reaches New 52-Week HighShould You Buy? - MarketBeat
A Closer Look at 10 Analyst Recommendations For Axsome Therapeutics - Benzinga
Axsome Therapeutics Inc earnings beat by $0.04, revenue topped estimates - Investing.com
Axsome Therapeutics (AXSM) Reports Q3 Loss, Tops Revenue Estimates - MSN
Axsome Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Axsome Therapeutics' (AXSM) Buy Rating Reiterated at Needham & Company LLC - MarketBeat
Axsome Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update - GlobeNewswire
Truist maintains buy on Axsome with $150 target on strong Auvelity sales - Investing.com UK
(AXSM) Proactive Strategies - Stock Traders Daily
Privium Fund Management B.V. Grows Stock Position in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Stock Position Decreased by Lindbrook Capital LLC - MarketBeat
Axsome Therapeutics Presents Data from Its Leading Neuroscience Pipeline at NEI Congress 2024 - GlobeNewswire
Axsome Therapeutics to Present Breakthrough CNS Data Across 3 Major Disorders at NEI 2024 | AXSM Stock News - StockTitan
Analysts Estimate Axsome Therapeutics (AXSM) to Report a Decline in Earnings: What to Look Out for - Yahoo Finance
Axsome Therapeutics (AXSM) to Release Earnings on Tuesday - MarketBeat
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Position Trimmed by abrdn plc - MarketBeat
Assenagon Asset Management S.A. Lowers Stake in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Analysts Set Axsome Therapeutics, Inc. (NASDAQ:AXSM) Target Price at $124.64 - MarketBeat
Axsome Therapeutics Inc (AXSM) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):